English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Plus monthly

Global: Zendy Tools annual

Global: Zendy Tools monthly

Global: Zendy Free Plan

Anemia, for which erythropoiesis-stimulating agents (ESAs) and ironsupplements (ISs) are used as preventive measures, presents importantdifficulties for hemodialysis patients. Nevertheless, the number of physiciansable to manage such medications appropriately is not keeping pace with therapid increase of hemodialysis patients. Moreover, the high cost of ESAsimposes heavy burdens on medical insurance systems. Anartificial-intelligence-supported anemia control system (AISACS) trained usingadministration direction data from experienced physicians has been developed bythe authors. For the system, appropriate data selection and rectificationtechniques play important roles. Decision making related to ESAs poses amulti-class classification problem for which a two-step classificationtechnique is introduced. Several validations have demonstrated that AISACSexhibits high performance with correct classification rates of 72-87% andclinically appropriate classification rates of 92-98%.

Artificial intelligence supported anemia control system (AISACS) to prevent anemia in maintenance hemodialysis patients